Company Encyclopedia
View More
name
Titan Pharma
TTNP.US
Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc.
4.396 T
TTNP.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    In Wednesday's after-market session, several health care stocks saw significant movements. Titan Pharma (NASDAQ:TTNP) shares surged by 37.9% to $6.3, with a market value of $6.3 million. Entero Therapeutics (NASDAQ:ENTO) rose 14.91% to $4.93, with a market cap of $7.9 million. Aspire Biopharma Hldgs (NASDAQ:ASBP) increased 14.16% to $0.24, valued at $10.2 million. Jade Biosciences (NASDAQ:JBIO) gained 9.76% to $10.0, with a market value of $281.5 million. Other notable gainers included rYojbaba (NASDAQ:RYOJ) and Profusa (NASDAQ:PFSA).

    Benzinga·
    US
    JBIO
    -1.50%
    US
    ASBP
    -6.15%
    US
    TTNP
    0.00%
    Benzinga·
    US
    JBIO
    -1.50%
    US
    ASBP
    -6.15%
    US
    TTNP
    0.00%

    Titan Pharmaceuticals Undergoes Leadership Restructuring

    Titan Pharmaceuticals (TTNP) has undergone a leadership restructuring, with stockholders losing rights per a merger agreement. Directors and officers resigned, and Chay Weei Jye was appointed as the sole director. Spark's analysis rates TTNP as Underperform due to declining revenues, negative cash flows, and operational inefficiencies. Technical analysis shows no clear momentum, and valuation metrics are unattractive. The current market cap is $5.67M, with an average trading volume of 48,649.

    Tip Ranks·
    US
    TTNP
    0.00%
    Tip Ranks·
    US
    TTNP
    0.00%

    12 Health Care Stocks Moving In Monday's After-Market Session

    In Monday's after-market session, several health care stocks saw significant movements. Check-Cap (CHEK) rose 25.5% to $2.66, with a market value of $4.3 million. Healthcare Triangle (HCTI) increased by 17.39% to $2.97, valued at $15.0 million. High Tide (HITI) shares went up 11.14% to $4.09, with a market cap of $298.6 million. Titan Pharma (TTNP) gained 8.86% to $4.79, valued at $5.7 million. Aytu BioPharma (AYTU) rose 7.93% to $2.51, with a market cap of $21.1 million, while Ernexa Therapeutics (ERNA) increased by 7.62% to $1.27, valued at $9.4 million.

    Benzinga·
    US
    ERNA
    -6.08%
    US
    TTNP
    0.00%
    US
    AYTU
    -0.99%
    Benzinga·
    US
    ERNA
    -6.08%
    US
    TTNP
    0.00%
    US
    AYTU
    -0.99%

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    In Tuesday's after-market session, several health care stocks experienced significant movements. NovaBay Pharmaceuticals (NBY) surged 51.3% to $1.36, with a market cap of $5.2 million. Salarius Pharmaceuticals (SLRX) rose 17.88% to $6.79, valued at $2.8 million. BioXcel Therapeutics (BTAI) increased 15.83% to $6.07, with a market cap of $75.1 million. Titan Pharma (TTNP) gained 14.68% to $5.7, valued at $6.5 million. Electromed (ELMD) rose 12.05% to $23.15, with a market cap of $169.3 million, following Q4 earnings. Outlook Therapeutics (OTLK) increased 8.14% to $2.92, valued at $131.9 million.

    Benzinga·
    US
    BTAI
    -5.43%
    US
    OTLK
    +2.62%
    US
    NBY
    -7.41%
    Benzinga·
    US
    BTAI
    -5.43%
    US
    OTLK
    +2.62%
    US
    NBY
    -7.41%

    TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP

    Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating the proposed merger between Titan Pharmaceuticals, Inc. (TTNP) and KE Sdn. Bhd. Shareholders of Titan are expected to own about 13.3% of the merged entity. The firm aims to assess the fairness and adequacy of the merger process for Titan's shareholders. Interested parties can contact KSF for more information regarding their legal rights related to the transaction.

    MorningStar·
    US
    TTNP
    0.00%
    MorningStar·
    US
    TTNP
    0.00%